Va Tech Wabag Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: October 28, 2025, 7:32 pm

Competitors of Va Tech Wabag Ltd

All Competitor Stocks of Va Tech Wabag Ltd

Quarterly Result

Last Updated: August 20, 2025, 1:40 am

Below is a detailed analysis of the quarterly data for Va Tech Wabag Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 734.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,156.00 Cr. (Mar 2025) to 734.00 Cr., marking a decrease of 422.00 Cr..
• For Expenses, as of Jun 2025, the value is 638.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1,015.00 Cr. (Mar 2025) to 638.00 Cr., marking a decrease of 377.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 96.00 Cr.. The value appears to be declining and may need further review. It has decreased from 141.00 Cr. (Mar 2025) to 96.00 Cr., marking a decrease of 45.00 Cr..
• For OPM %, as of Jun 2025, the value is 13.00%. The value appears strong and on an upward trend. It has increased from 12.00% (Mar 2025) to 13.00%, marking an increase of 1.00%.
• For Other Income, as of Jun 2025, the value is 11.00 Cr.. The value appears to be declining and may need further review. It has decreased from 13.00 Cr. (Mar 2025) to 11.00 Cr., marking a decrease of 2.00 Cr..
• For Interest, as of Jun 2025, the value is 19.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 22.00 Cr. (Mar 2025) to 19.00 Cr., marking a decrease of 3.00 Cr..
• For Depreciation, as of Jun 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 87.00 Cr.. The value appears to be declining and may need further review. It has decreased from 131.00 Cr. (Mar 2025) to 87.00 Cr., marking a decrease of 44.00 Cr..
• For Tax %, as of Jun 2025, the value is 24.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 24.00%.
• For Net Profit, as of Jun 2025, the value is 66.00 Cr.. The value appears to be declining and may need further review. It has decreased from 100.00 Cr. (Mar 2025) to 66.00 Cr., marking a decrease of 34.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 10.58. The value appears to be declining and may need further review. It has decreased from 16.00 (Mar 2025) to 10.58, marking a decrease of 5.42.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 4:12 am

Growth

Last Updated: September 5, 2025, 1:50 pm

Balance Sheet

Last Updated: June 16, 2025, 11:08 am

Below is a detailed analysis of the balance sheet data for Va Tech Wabag Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 12.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 12.00 Cr..
• For Reserves, as of Mar 2025, the value is 2,128.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,806.00 Cr. (Mar 2024) to 2,128.00 Cr., marking an increase of 322.00 Cr..
• For Borrowings, as of Mar 2025, the value is 362.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 289.00 Cr. (Mar 2024) to 362.00 Cr., marking an increase of 73.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 2,766.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,467.00 Cr. (Mar 2024) to 2,766.00 Cr., marking an increase of 299.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 5,267.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,574.00 Cr. (Mar 2024) to 5,267.00 Cr., marking an increase of 693.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 67.00 Cr.. The value appears to be declining and may need further review. It has decreased from 72.00 Cr. (Mar 2024) to 67.00 Cr., marking a decrease of 5.00 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Investments, as of Mar 2025, the value is 69.00 Cr.. The value appears strong and on an upward trend. It has increased from 67.00 Cr. (Mar 2024) to 69.00 Cr., marking an increase of 2.00 Cr..
• For Other Assets, as of Mar 2025, the value is 5,131.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,435.00 Cr. (Mar 2024) to 5,131.00 Cr., marking an increase of 696.00 Cr..
• For Total Assets, as of Mar 2025, the value is 5,267.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,574.00 Cr. (Mar 2024) to 5,267.00 Cr., marking an increase of 693.00 Cr..

Notably, the Reserves (2,128.00 Cr.) exceed the Borrowings (362.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Va Tech Wabag Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 50.09. This value is within the healthy range. It has increased from 39.49 (Mar 24) to 50.09, marking an increase of 10.60.
• For Diluted EPS (Rs.), as of Mar 25, the value is 49.37. This value is within the healthy range. It has increased from 39.49 (Mar 24) to 49.37, marking an increase of 9.88.
• For Cash EPS (Rs.), as of Mar 25, the value is 48.15. This value is within the healthy range. It has increased from 43.27 (Mar 24) to 48.15, marking an increase of 4.88.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 345.14. It has increased from 294.19 (Mar 24) to 345.14, marking an increase of 50.95.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 345.14. It has increased from 294.19 (Mar 24) to 345.14, marking an increase of 50.95.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 531.29. It has increased from 460.71 (Mar 24) to 531.29, marking an increase of 70.58.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 75.31. This value is within the healthy range. It has increased from 67.60 (Mar 24) to 75.31, marking an increase of 7.71.
• For PBIT / Share (Rs.), as of Mar 25, the value is 74.35. This value is within the healthy range. It has increased from 66.24 (Mar 24) to 74.35, marking an increase of 8.11.
• For PBT / Share (Rs.), as of Mar 25, the value is 61.65. This value is within the healthy range. It has increased from 54.77 (Mar 24) to 61.65, marking an increase of 6.88.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 47.19. This value is within the healthy range. It has increased from 41.92 (Mar 24) to 47.19, marking an increase of 5.27.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 47.63. This value is within the healthy range. It has increased from 39.61 (Mar 24) to 47.63, marking an increase of 8.02.
• For PBDIT Margin (%), as of Mar 25, the value is 14.17. This value is within the healthy range. It has decreased from 14.67 (Mar 24) to 14.17, marking a decrease of 0.50.
• For PBIT Margin (%), as of Mar 25, the value is 13.99. This value is within the healthy range. It has decreased from 14.37 (Mar 24) to 13.99, marking a decrease of 0.38.
• For PBT Margin (%), as of Mar 25, the value is 11.60. This value is within the healthy range. It has decreased from 11.88 (Mar 24) to 11.60, marking a decrease of 0.28.
• For Net Profit Margin (%), as of Mar 25, the value is 8.88. This value is within the healthy range. It has decreased from 9.09 (Mar 24) to 8.88, marking a decrease of 0.21.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 8.96. This value is within the healthy range. It has increased from 8.59 (Mar 24) to 8.96, marking an increase of 0.37.
• For Return on Networth / Equity (%), as of Mar 25, the value is 13.79. This value is below the healthy minimum of 15. It has increased from 13.50 (Mar 24) to 13.79, marking an increase of 0.29.
• For Return on Capital Employeed (%), as of Mar 25, the value is 16.78. This value is within the healthy range. It has decreased from 16.97 (Mar 24) to 16.78, marking a decrease of 0.19.
• For Return On Assets (%), as of Mar 25, the value is 5.60. This value is within the healthy range. It has increased from 5.36 (Mar 24) to 5.60, marking an increase of 0.24.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.08. This value is below the healthy minimum of 0.2. It has decreased from 0.10 (Mar 24) to 0.08, marking a decrease of 0.02.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.16. This value is within the healthy range. It has increased from 0.15 (Mar 24) to 0.16, marking an increase of 0.01.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.66. It has increased from 0.65 (Mar 24) to 0.66, marking an increase of 0.01.
• For Current Ratio (X), as of Mar 25, the value is 1.70. This value is within the healthy range. It has increased from 1.68 (Mar 24) to 1.70, marking an increase of 0.02.
• For Quick Ratio (X), as of Mar 25, the value is 1.68. This value is within the healthy range. It has increased from 1.67 (Mar 24) to 1.68, marking an increase of 0.01.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 71.40. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 71.40, marking an increase of 71.40.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 5.93. This value is within the healthy range. It has increased from 5.89 (Mar 24) to 5.93, marking an increase of 0.04.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.71. This value is within the healthy range. It has increased from 4.66 (Mar 24) to 4.71, marking an increase of 0.05.
• For Enterprise Value (Cr.), as of Mar 25, the value is 8,429.19. It has increased from 4,505.56 (Mar 24) to 8,429.19, marking an increase of 3,923.63.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.56. This value is within the healthy range. It has increased from 1.58 (Mar 24) to 2.56, marking an increase of 0.98.
• For EV / EBITDA (X), as of Mar 25, the value is 18.05. This value exceeds the healthy maximum of 15. It has increased from 10.75 (Mar 24) to 18.05, marking an increase of 7.30.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.74. This value is within the healthy range. It has increased from 1.66 (Mar 24) to 2.74, marking an increase of 1.08.
• For Price / BV (X), as of Mar 25, the value is 4.21. This value exceeds the healthy maximum of 3. It has increased from 2.60 (Mar 24) to 4.21, marking an increase of 1.61.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.74. This value is within the healthy range. It has increased from 1.66 (Mar 24) to 2.74, marking an increase of 1.08.
• For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.05 (Mar 24) to 0.03, marking a decrease of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness